WAYNE, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced key milestones in the release of two new catheters: the U.S. Food and Drug Administration (FDA) 510(k) clearance of the Triumph™ Catheter, and the first clinical use of GuideLiner^® Coast™ Catheter.  

The Triumph™ Catheter is the latest addition to the Teleflex family of catheters, which includes the GuideLiner^® V3 Catheter, TrapLiner^® Catheter, and Turnpike^® Catheters. Designed in collaboration with Bill Nicholson, MD, Director of Interventional Cardiology at Emory Healthcare, Atlanta, GA, the Triumph™ Catheter features a unique design with six wire exit ports for precise wire advancement and clear visualization.   “In complex cases, the ability to better navigate tortuous anatomy has long been a challenge,” said Dr. Nicholson. “The Triumph™ Catheter’s nitinol ports and cage bring navigation and control to a new level, and I am excited that Teleflex will enable interventional cardiologists to readily access this important technology.”

The GuideLiner^® Coast™ Catheter adds a hydrophilic option to Teleflex’s market-leading guide extension portfolio—anchored by the flagship GuideLiner^® V3 Catheter—enabling physicians to select the level of deliverability and backup support needed for specific cases.¹ Earlier this year, the GuideLiner^® Coast™ Catheter was first used in a clinical procedure at the UW Medicine Heart Institute in Seattle, Washington.

“Teleflex is committed to providing more options in the cath lab to help interventionalists address the specific needs of their patients,” said Scott Holstine, President and General Manager of Teleflex’s Interventional business unit. “The Triumph™ Catheter and the GuideLiner^® Coast™ Catheter reflect our focus on providing physicians with new choices and technologies engineered to address unmet clinical needs, personal preference and technique, and the challenges of complex anatomy.”

The GuideLiner^® Coast™ Catheter is currently in a limited market release phase, with full market release anticipated later this year. Both catheters will be on display as part of Teleflex’s hands-on workshops during CTO Plus: Complex CTO & Higher Risk PCI, February 23-24 at the New York Marriott Marquis in Times Square.     

About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow^®, Deknatel^®, LMA^®, Pilling^®, QuikClot^®, Rusch^®, UroLift^®, and Weck^® – trusted brands united by a common sense of purpose.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

*Dr. Nicholson is a paid consultant of Teleflex Incorporated.

CAUTION: Federal (USA) law restricts these devices for sale or use by or on the order of a physician.

Teleflex, the Teleflex logo, Arrow, Coast, Deknatel, GuideLiner, LMA, Pilling, QuikClot, Rusch, Triumph, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates in the U.S. and/or other countries. Information in this document is not a substitute for the product Instructions for Use.  Refer to the Instructions for Use for a complete listing of the indications, contraindications, warnings, and precautions. Not all products may be available in all countries. Please contact your local representative. 

© 2023 Teleflex Incorporated. All rights reserved. MC-008718 Rev 0.

Contacts:

For Teleflex Incorporated:
Lawrence Keusch
Vice President, Investor Relations and Strategy Development

John Hsu, CFA
Vice President, Investor Relations

investor.relations@teleflex.com
610.948.2836

References:

1. Data on File from IQVIA, as of 10/5/22.